SCHEMBL20412079

SCHEMBL20412079

Cc1ccc2c(c1)Sc1ccccc1N2CCCCN1CCC(N2CCCC2)CC1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM1A O60341 14/20 0.68
▸ FPR2 P25090 4/20 0.50
▸ LMNA P02545 2/20 0.47
▸ CHRM2 P08172 2/20 0.47
▸ HTR1A P08908 2/20 0.47
▸ ADRA2A P08913 2/20 0.47
▸ CHRM1 P11229 2/20 0.47
▸ DRD1 P21728 2/20 0.47
▸ SLC6A2 P23975 2/20 0.47
▸ MAPK1 P28482 2/20 0.47
▸ SLC6A4 P31645 2/20 0.47
▸ ADRA1A P35348 2/20 0.47
▸ OPRM1 P35372 2/20 0.47
▸ DRD3 P35462 2/20 0.47
▸ SLC6A3 Q01959 2/20 0.47
▸ KCNH2 Q12809 2/20 0.47
▸ PGR P06401 1/20 0.47
▸ TBXA2R P21731 1/20 0.47
▸ ACHE P22303 1/20 0.47
▸ PTGS1 P23219 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31673733 1.00 KDM1A (0.68) KDM1AFPR2LMNACHRM2HTR1A
SCHEMBL20412075 0.99 KDM1A (0.70) KDM1AFPR2LMNACHRM2HTR1A
SCHEMBL31673756 0.98 KDM1A (0.68) KDM1AFPR2LMNACHRM2HTR1A
SCHEMBL20412098 0.98 KDM1A (0.68) KDM1AFPR2LMNACHRM2HTR1A
SCHEMBL20412076 0.97 KDM1A (0.70) KDM1AFPR2LMNACHRM2HTR1A
SCHEMBL31673781 0.97 KDM1A (0.70) KDM1AFPR2LMNACHRM2HTR1A
SCHEMBL20412134 0.94 KDM1A (0.68) KDM1AFPR2LMNACHRM2HTR1A
SCHEMBL31673722 0.94 KDM1A (0.68) KDM1AFPR2LMNACHRM2HTR1A
SCHEMBL20412149 0.93 KDM1A (0.70) KDM1AFPR2LMNACHRM2HTR1A
SCHEMBL20425968 0.92 KDM1A (0.68) KDM1AFPR2LMNACHRM2HTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230330095-A1 PHARMACEUTICAL COMPOSITION FOR ANTI-CANCER COMPRISING NUPR1 ISOFORM A INHIBITOR SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) 2023-10-19 — — US claimed
EP-4260861-A1 PHARMACEUTICAL COMPOSITION FOR ANTI-CANCER COMPRISING NUPR1 ISOFORM A INHIBITOR Seoul National University R & DB Foundation (KR) 2023-10-18 — — EP claimed
US-10035795-B1 Phenothiazine derivatives having CaM inhibitory activity KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2018-07-31 — — US claimed
US-20230330095-A1 PHARMACEUTICAL COMPOSITION FOR ANTI-CANCER COMPRISING NUPR1 ISOFORM A INHIBITOR SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) 2023-10-19 — — US disclosed
EP-4260861-A1 PHARMACEUTICAL COMPOSITION FOR ANTI-CANCER COMPRISING NUPR1 ISOFORM A INHIBITOR Seoul National University R & DB Foundation (KR) 2023-10-18 — — EP disclosed
US-10035795-B1 Phenothiazine derivatives having CaM inhibitory activity KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2018-07-31 — — US disclosed
US-10035795-B1 Phenothiazine derivatives having CaM inhibitory activity KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2018-07-31 — — US disclosed
US-10035795-B1 Phenothiazine derivatives having CaM inhibitory activity KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2018-07-31 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230330095-A1 PHARMACEUTICAL COMPOSITION FOR ANTI-CANCER COMPRISING NUPR1 ISOFORM A INHIBITOR NUP205, NUP50, NUP188 KDM1A 2069/4885FPR2 4687/4885LMNA 236/4885
US-10035795-B1 Phenothiazine derivatives having CaM inhibitory activity CALM1, CAMK4, CAMK1 KDM1A 3642/4885FPR2 3304/4885LMNA 2841/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback